refractory/relapsed
Showing 1 - 25 of >10,000
Refractory/Relapsed Autoimmune Hemolytic Anemia Trial in Tianjin (Zanubrutinib)
Not yet recruiting
- Refractory/Relapsed Autoimmune Hemolytic Anemia
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Aug 27, 2023
Bortezomib, Acute Myeloid Leukemia Trial in Wuhan (DAG pre-excitation regimen with Bortezomib)
Recruiting
- Bortezomib
- Acute Myeloid Leukemia
- DAG pre-excitation regimen with Bortezomib
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jul 31, 2023
Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)
Recruiting
- Relapse/Refractory Multiple Myeloma
- DeepTag-GPRC5D Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023
Warm Autoimmune Hemolytic Anemia Trial in Beijing (Sirolimus)
Not yet recruiting
- Warm Autoimmune Hemolytic Anemia
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 21, 2023
Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 23, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined
Recruiting
- Peripheral T Cell Lymphoma
- +2 more
- Chidamide combined with Duvillisib
-
Xiamen, Fujian, ChinaThe First Affiliated Hosptial of Xiamen University
Nov 28, 2023
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- CD5 CAR-T
-
Beijing, Beijing, ChinaXuanwu Hospital Capital Medical University
Oct 23, 2022
Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)
Not yet recruiting
- Leukemia, Myeloid, Acute
- CD33KO-HSPC; CART33
- (no location specified)
Jul 13, 2023
Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)
Not yet recruiting
- Hodgkin Lymphoma
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Aug 18, 2022
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)
Recruiting
- Central Nervous System Lymphoma
- Human CD19-CD22 Targeted T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)
Recruiting
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
- BCMA Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022
Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in
Not yet recruiting
- Neuroblastoma
- +2 more
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
-
Atlanta, GeorgiaChildren's Healthcare of Atlanta
Oct 6, 2022
B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)
Recruiting
- B-Cell Leukemia
- B Cell Lymphoma
- anti-CD19 UCAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022
Auto/Allo Tandem Transplant for Relapsed B-NHL
Completed
- Non Hodgkin Lymphoma
- auto transplant followed by allo transplant
- (no location specified)
Oct 24, 2022
Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,
Not yet recruiting
- Refractory Non-Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +2 more
-
Miami, FloridaUniversity of Miami
Aug 3, 2022
Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))
Not yet recruiting
- Refractory Cancer
- Relapsed Cancer
- Drug Sensitivity Test (DST)
-
Weston, FloridaLerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023
Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- BMS-986453
- +2 more
-
Köln, GermanyLocal Institution - 0017
Dec 4, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia Recurrent
- CD123-CAR-NK cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022
Acute Myeloid Leukemia Trial in Nanjing (Chidamide, Cladribine)
Recruiting
- Acute Myeloid Leukemia
-
Nanjing, Jiangsu, ChinaDepartment of Hematology, Zhongda Hospital Southeast University,
Apr 23, 2022
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital, Soochow University
Jul 31, 2023
PET-CT Imaging in Relapsed/Refractory Acute Leukemias
Not yet recruiting
- B Cell
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 4, 2023